EMA Recommends Extending Indications for Lisocabtagene Maraleucel By Ogkologos - November 12, 2025 85 0 Facebook Twitter Google+ Pinterest WhatsApp New indication concerns the treatment of adult patients with relapsed or refractory mantle cell lymphoma Source RELATED ARTICLESMORE FROM AUTHOR Noninferiority of OS with 3 Months Compared to 6 Months of Adjuvant Chemotherapy for Patients with High-Risk Stage III Colorectal Cancer Patient Guide on Bone Health in Cancer Now Available Also in French Lung Cancer Death Rates Among Women in Europe Are Finally Levelling Off MOST POPULAR COVID-19, Vaccines, and the Immune System: Emerging Research from NCI’s SeroNet August 30, 2021 FDA Approves BCMA-Targeted CAR T-Cell Therapy for Multiple Myeloma April 14, 2021 How cancer hijacks cell death: a new view of metastasis September 17, 2021 VA Study Finds No Disparities in Prostate Cancer Deaths with Equal... February 18, 2020 Load more HOT NEWS NHS England change of chief executive – what does it mean... EMA Recommends Granting a Conditional Marketing Authorisation for Tafasitamab Gynaecological Cancers: Immunotherapy and Novel Targeted Drug Appear Beneficial in Group... Efficacy of Sintilimab in the Adjuvant Treatment for Patients with Resected,...
